Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| endothelial cell | 12 studies | 26% ± 8% | |
| naive thymus-derived CD4-positive, alpha-beta T cell | 9 studies | 32% ± 12% | |
| CD4-positive, alpha-beta T cell | 9 studies | 25% ± 6% | |
| CD8-positive, alpha-beta T cell | 8 studies | 25% ± 8% | |
| T cell | 7 studies | 25% ± 9% | |
| naive thymus-derived CD8-positive, alpha-beta T cell | 7 studies | 29% ± 13% | |
| regulatory T cell | 7 studies | 24% ± 4% | |
| endothelial cell of lymphatic vessel | 6 studies | 25% ± 4% | |
| natural killer cell | 5 studies | 25% ± 7% | |
| effector CD8-positive, alpha-beta T cell | 4 studies | 30% ± 11% | |
| endothelial cell of vascular tree | 4 studies | 27% ± 10% | |
| CD16-positive, CD56-dim natural killer cell, human | 3 studies | 21% ± 6% | |
| mucosal invariant T cell | 3 studies | 26% ± 3% | |
| exhausted T cell | 3 studies | 37% ± 9% | |
| macrophage | 3 studies | 23% ± 7% | |
| CD8-positive, alpha-beta memory T cell | 3 studies | 23% ± 5% | |
| T follicular helper cell | 3 studies | 27% ± 10% | |
| CD4-positive, alpha-beta memory T cell | 3 studies | 24% ± 6% |
Insufficient scRNA-seq data for expression of GIMAP5 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| kidney | 98% | 1574.25 | 87 / 89 | 36% | 1.04 | 325 / 901 |
| lung | 100% | 6180.79 | 578 / 578 | 20% | 0.43 | 229 / 1155 |
| breast | 100% | 4000.78 | 459 / 459 | 12% | 0.23 | 131 / 1118 |
| thymus | 100% | 3176.53 | 652 / 653 | 10% | 0.17 | 62 / 605 |
| bladder | 100% | 1629.95 | 21 / 21 | 6% | 0.13 | 29 / 504 |
| intestine | 98% | 1849.72 | 951 / 966 | 6% | 0.14 | 34 / 527 |
| uterus | 99% | 2308.56 | 169 / 170 | 3% | 0.05 | 15 / 459 |
| esophagus | 92% | 1396.43 | 1323 / 1445 | 9% | 0.16 | 17 / 183 |
| adrenal gland | 97% | 1192.34 | 251 / 258 | 3% | 0.05 | 8 / 230 |
| adipose | 100% | 4698.41 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| spleen | 100% | 7642.83 | 241 / 241 | 0% | 0 | 0 / 0 |
| stomach | 91% | 1022.77 | 325 / 359 | 9% | 0.20 | 26 / 286 |
| heart | 99% | 1870.53 | 854 / 861 | 0% | 0 | 0 / 0 |
| prostate | 96% | 1286.87 | 234 / 245 | 3% | 0.07 | 17 / 502 |
| peripheral blood | 93% | 2975.61 | 867 / 929 | 0% | 0 | 0 / 0 |
| muscle | 87% | 834.89 | 700 / 803 | 0% | 0 | 0 / 0 |
| blood vessel | 78% | 1165.91 | 1040 / 1335 | 0% | 0 | 0 / 0 |
| skin | 60% | 684.29 | 1086 / 1809 | 14% | 0.36 | 66 / 472 |
| brain | 55% | 458.00 | 1440 / 2642 | 7% | 0.10 | 47 / 705 |
| liver | 47% | 429.17 | 106 / 226 | 5% | 0.08 | 22 / 406 |
| lymph node | 0% | 0 | 0 / 0 | 52% | 2.17 | 15 / 29 |
| ovary | 48% | 478.39 | 87 / 180 | 2% | 0.03 | 8 / 430 |
| pancreas | 33% | 210.67 | 109 / 328 | 17% | 0.32 | 30 / 178 |
| tonsil | 0% | 0 | 0 / 0 | 9% | 0.12 | 4 / 45 |
| eye | 0% | 0 | 0 / 0 | 3% | 0.04 | 2 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0005765 | Cellular component | lysosomal membrane |
| GO_0032585 | Cellular component | multivesicular body membrane |
| GO_0005525 | Molecular function | GTP binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | GIMAP5 |
| Protein name | GTPase IMAP family member 5 (Immune-associated nucleotide-binding protein 5) (Immunity-associated nucleotide 4-like 1 protein) (Immunity-associated nucleotide 5 protein) (IAN-5) (hIAN5) (Immunity-associated protein 3) |
| Synonyms | IMAP3 IAN4L1 IAN5 |
| Description | FUNCTION: Plays a role in T lymphocyte development and the optimal generation of CD4/CD8 double-positive thymocytes (By similarity). Inhibitor of GSK3A, possibly by sequestering GSK3A in cytoplasmic vesicles and impairing its translocation to the nucleus. Consequently, impairs GSK3A-dependent transcriptional program and regulation of the DNA damage response occurring during T cells proliferation . Required for the survival of peripheral T cells, natural killer (NK) and NK T-cell development and the maintenance of normal liver function (By similarity). May promote the survival of mature T lymphocytes upon cytokine withdrawal (By similarity). May regulate Ca(2+) homeostasis by modulating lysosomal Ca(2+) stores, preventing its accumulation in the absence of T cell activation (By similarity). May play a role in mitochondrial DNA segregation in hematopoietic tissues (By similarity). Is a regulator of liver endothelial cell homeostasis (By similarity). . |
| Accessions | ENST00000498181.6 [Q96F15-1] ENST00000358647.5 [Q96F15-1] Q96F15 |